Abstract: TH-OR35
Daily Caffeine Consumption and Risk of AKI Related to Platinum-Salt Chemotherapy: A Prospective Cohort Study
Session Information
- Onco-Nephrology Updates in Practice
October 22, 2020 | Location: Simulive
Abstract Time: 05:00 PM - 07:00 PM
Category: Onco-Nephrology
- 1500 Onco-Nephrology
Authors
- Hamroun, Aghiles, Centre Hospitalier Regional Universitaire de Lille, Lille, Hauts-de-France, France
- Antoine, Decaestecker, Centre Hospitalier Regional Universitaire de Lille, Lille, Hauts-de-France, France
- Blum, David, Universite de Lille, Lille, Hauts-de-France, France
- Cauffiez, Christelle, Universite de Lille, Lille, Hauts-de-France, France
- Glowacki, François, Centre Hospitalier Regional Universitaire de Lille, Lille, Hauts-de-France, France
Background
Although their efficacy has been well-established in Oncology, the use of platinum salts remains limited due to the occurrence of acute kidney injury (AKI). Caffeine has been suggested as a potential pathophysiological actor of platinum salt-induced AKI, through its hemodynamic effects. This work aims to study the association between caffeine consumption and the risk of platinum salt-induced AKI.
Methods
We conducted a single-center prospective cohort study that has included 108 consecutive thoracic cancer patients receiving a first-line platinum-salt chemotherapy between January 2017 and December 2018. Before the first course of chemotherapy, they were all invited to fill in a previously validated auto-questionnaire, designed for a detailed evaluation of their daily caffeine consumption (mg/day). The association of daily caffeine consumption with the risk of platinum-salt induced AKI was estimated by cause-specific Cox proportional hazard model adjusted for several known confounders (baseline renal function and serum albumin level, nature and dose of platinum-salt, tobacco exposure, and Performans status).
Results
Overall, 34 patients (31.5%) (mean age 61.7 years, 65% men, 80% tobacco users) experienced a platinum salt-induced AKI (67% grade 1) and 47 (43.5%) died during follow-up (6.2 months [3.4; 8.4]). The group of high-caffeine consumption (≥ 386mg/day) had a twice higher risk of AKI (HR=2.12 [1.01; 4.45]) in the fully adjusted model. The cumulative incidence of AKI (considering the competing risk of death) was also significantly increased in the high-caffeine consumption group (p=0.03, see figure 1).
Conclusion
In a population of thoracic cancer patients, the group of high-caffeine consumption was exposed to a significantly higher risk of platinum salt-induced AKI.